BRCA1 and cancer: The percentage of BRCA1/2 germline mutation carriers in Chinese NSCLC patients (86/9010 = 0.95 %) was significantly lower than that in Chinese breast and ovary cancer patients (1481/20,523 = 7.2 %) (P < 0.001), suggesting a cancer-type dependent incidence of BRCA1/2 germline mutations.